Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Aortic Valve Replacement | Research article

Optimal INR level for warfarin therapy after mechanical mitral valve replacement

Authors: Itthidet Kamthornthanakarn, Rungroj Krittayaphong

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Data are scarce regarding the optimal international normalized ratio (INR) in Thai patients who require warfarin therapy after mechanical mitral valve replacement. Accordingly, the aim of this study was to identify the optimal INR level for warfarin therapy after mechanical mitral valve replacement in Thai patients.

Methods

This is a retrospective cohort study design. We retrospectively reviewed the medical records of mechanical mitral valve replacement patients who received warfarin therapy at Siriraj Hospital. INR range was classified into 6 groups (< 2, 2.0–2.4, 2.5–2.9, 3.0–3.4, 3.5–4.5, and > 4.5). The optimal INR level was defined as the level with the lowest incidence density of thromboembolic or hemorrhagic complications.

Results

Two hundred patients were included and followed over a period of 707.81 patient-years. Mean duration of follow-up was 3.53 ± 1.27 years. Eleven patients experienced 13 thromboembolic events (3.42 per 100 patient-years), and 12 patients experienced 18 total bleeding events (5.50 per 100 patient-years). Intracranial bleeding occurred in 3 patients (2.62 per 100 patient-years). The percentage of patient time spent within INR 2.5–3.4, INR < 2.5, and INR > 3.4 was 41.96, 54.04, and 4%, respectively. The overall event rate was lowest in the 2.0 to 3.4 INR range. Statistically significant differences were observed between INR 2.3 to 4 and < 2 (p < 0.001) and between INR 2.3 to 4 and > 3.4 (p < 0.001).

Conclusions

The optimal INR level was within the range of 2.0 to 3.4 in our cohort of Thai mechanical mitral valve replacement patients.
Literature
1.
go back to reference Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, Pauker SG. Antithrombotic therapy in valvular heart disease--native and prosthetic: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):457S–82S.CrossRef Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, Pauker SG. Antithrombotic therapy in valvular heart disease--native and prosthetic: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):457S–82S.CrossRef
2.
go back to reference Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635–41.CrossRef Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994;89(2):635–41.CrossRef
3.
go back to reference Kulik A, Rubens FD, Wells PS, Kearon C, Mesana TG, van Berkom J, Lam BK. Early postoperative anticoagulation after mechanical valve replacement: a systematic review. Ann Thorac Surg. 2006;81(2):770–81.CrossRef Kulik A, Rubens FD, Wells PS, Kearon C, Mesana TG, van Berkom J, Lam BK. Early postoperative anticoagulation after mechanical valve replacement: a systematic review. Ann Thorac Surg. 2006;81(2):770–81.CrossRef
4.
go back to reference Fuster V, Pumphrey CW, McGoon MD, Chesebro JH, Pluth JR, McGoon DC. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. Circulation. 1982;66(2 Pt 2):I157–61.PubMed Fuster V, Pumphrey CW, McGoon MD, Chesebro JH, Pluth JR, McGoon DC. Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. Circulation. 1982;66(2 Pt 2):I157–61.PubMed
5.
go back to reference Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e576S–600S.CrossRef Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e576S–600S.CrossRef
6.
go back to reference Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, et al. Guidelines on the management of valvular heart disease (version 2012): the joint task force on the management of Valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42(4):S1–44.CrossRef Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, et al. Guidelines on the management of valvular heart disease (version 2012): the joint task force on the management of Valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg. 2012;42(4):S1–44.CrossRef
7.
go back to reference Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):2438–88.CrossRef Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):2438–88.CrossRef
8.
go back to reference Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B, Prendergast B, Iung B, Bjornstad H, Leport C, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J. 2005;26(22):2463–71.CrossRef Butchart EG, Gohlke-Barwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B, Prendergast B, Iung B, Bjornstad H, Leport C, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J. 2005;26(22):2463–71.CrossRef
9.
go back to reference Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309–15.CrossRef Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309–15.CrossRef
10.
go back to reference Tse HF, Wang YJ, Ahmed Ai-Abdullah M, Pizarro-Borromeo AB, Chiang CE, Krittayaphong R, Singh B, Vora A, Wang CX, Zubaid M, et al. Stroke prevention in atrial fibrillation--an Asian stroke perspective. Heart Rhythm. 2013;10(7):1082–8.CrossRef Tse HF, Wang YJ, Ahmed Ai-Abdullah M, Pizarro-Borromeo AB, Chiang CE, Krittayaphong R, Singh B, Vora A, Wang CX, Zubaid M, et al. Stroke prevention in atrial fibrillation--an Asian stroke perspective. Heart Rhythm. 2013;10(7):1082–8.CrossRef
11.
go back to reference Zhou XM, Zhuang W, Hu JG, Li JM, Yu JF, Jiang L. Low-dose anticoagulation in Chinese patients with mechanical heart valves. Asian Cardiovasc Thorac Ann. 2005;13(4):341–4.CrossRef Zhou XM, Zhuang W, Hu JG, Li JM, Yu JF, Jiang L. Low-dose anticoagulation in Chinese patients with mechanical heart valves. Asian Cardiovasc Thorac Ann. 2005;13(4):341–4.CrossRef
12.
go back to reference Mori T, Asano M, Ohtake H, Bitoh A, Sekiguchi S, Matsuo Y, Aiba M, Yamada M, Kawada T, Takaba T. Anticoagulant therapy after prosthetic valve replacement -optimal PT-INR in Japanese patients. Ann Thorac Cardiovasc Surg. 2002;8(2):83–7.PubMed Mori T, Asano M, Ohtake H, Bitoh A, Sekiguchi S, Matsuo Y, Aiba M, Yamada M, Kawada T, Takaba T. Anticoagulant therapy after prosthetic valve replacement -optimal PT-INR in Japanese patients. Ann Thorac Cardiovasc Surg. 2002;8(2):83–7.PubMed
13.
go back to reference Haibo Z, Jinzhong L, Yan L, Xu M. Low-intensity international normalized ratio (INR) oral anticoagulant therapy in Chinese patients with mechanical heart valve prostheses. Cell Biochem Biophys. 2012;62(1):147–51.CrossRef Haibo Z, Jinzhong L, Yan L, Xu M. Low-intensity international normalized ratio (INR) oral anticoagulant therapy in Chinese patients with mechanical heart valve prostheses. Cell Biochem Biophys. 2012;62(1):147–51.CrossRef
14.
go back to reference Torn M, Cannegieter SC, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med. 2009;169(13):1203–9.CrossRef Torn M, Cannegieter SC, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med. 2009;169(13):1203–9.CrossRef
15.
go back to reference Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.CrossRef Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.CrossRef
16.
go back to reference Schulman S, Kearon C, Subcommittee on control of anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.CrossRef Schulman S, Kearon C, Subcommittee on control of anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.CrossRef
17.
go back to reference Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736–47.CrossRef Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736–47.CrossRef
18.
go back to reference Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.CrossRef Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.CrossRef
19.
go back to reference Koertke H, Zittermann A, Wagner O, Ennker J, Saggau W, Sack FU, Cremer J, Huth C, Braccio M, Musumeci F, et al. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement. Ann Thorac Surg. 2010;90(5):1487–93.CrossRef Koertke H, Zittermann A, Wagner O, Ennker J, Saggau W, Sack FU, Cremer J, Huth C, Braccio M, Musumeci F, et al. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement. Ann Thorac Surg. 2010;90(5):1487–93.CrossRef
20.
go back to reference Acar J, Iung B, Boissel JP, Samama MM, Michel PL, Teppe JP, Pony JC, Breton HL, Thomas D, Isnard R, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation. 1996;94(9):2107–12.CrossRef Acar J, Iung B, Boissel JP, Samama MM, Michel PL, Teppe JP, Pony JC, Breton HL, Thomas D, Isnard R, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation. 1996;94(9):2107–12.CrossRef
21.
go back to reference Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Munoz D, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.CrossRef Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Munoz D, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.CrossRef
22.
go back to reference Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(25):e1159–95.CrossRef Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017;135(25):e1159–95.CrossRef
23.
go back to reference Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, et al. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016;223:543–7.CrossRef Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, et al. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry. Int J Cardiol. 2016;223:543–7.CrossRef
24.
go back to reference Poli D, Antonucci E, Dentali F, Erba N, Testa S, Tiraferri E, Palareti G, Italian Federation of Anticoagulation C. Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. Neurology. 2014;82(12):1020–6.CrossRef Poli D, Antonucci E, Dentali F, Erba N, Testa S, Tiraferri E, Palareti G, Italian Federation of Anticoagulation C. Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study. Neurology. 2014;82(12):1020–6.CrossRef
25.
go back to reference Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One. 2016;11(10):e0164076.CrossRef Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One. 2016;11(10):e0164076.CrossRef
26.
go back to reference Shen AY, Contreras R, Sobnosky S, Shah AI, Ichiuji AM, Jorgensen MB, Brar SS, Chen W. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults--a cross-sectional study. J Natl Med Assoc. 2010;102(10):906–13.CrossRef Shen AY, Contreras R, Sobnosky S, Shah AI, Ichiuji AM, Jorgensen MB, Brar SS, Chen W. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults--a cross-sectional study. J Natl Med Assoc. 2010;102(10):906–13.CrossRef
Metadata
Title
Optimal INR level for warfarin therapy after mechanical mitral valve replacement
Authors
Itthidet Kamthornthanakarn
Rungroj Krittayaphong
Publication date
01-12-2019

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue